Table 1.

Baseline characteristics of the modified intention-to-treat cohort

	Palonosetron arm	Granisetron arm
	(n = 555)	(n = 559)
Gender, n (%)
Female	326 (58.7)	324 (58.0)
Male	229 (41.3)	235 (42.0)
Age, years
Mean (SD)	58.4 (10.4)	58.0 (10.5)
≥55 years, n (%)	376 (67.7)	380 (68.0)
<55 years, n (%)	179 (32.3)	179 (32.0)
Tumor type, n (%)
Non-small cell lung cancer	248 (44.7)	249 (44.5)
Small cell lung cancer	47 (8.5)	52 (9.3)
Breast cancer	239 (43.1)	236 (42.2)
Others	21 (3.8)	22 (3.9)
Chemotherapy, n (%)
Cisplatin	316 (56.9)	323 (57.8)
AC/EC	239 (43.1)	236 (42.2)
Previous chemotherapy, n (%)
Naive	519 (93.5)	516 (92.3)
Non-naive	36 (6.5)	43 (7.7)

AC/EC doxorubicin or epirubicin with cyclophosphamide, SD standard deviation